# 注射用单硝酸异山梨酯治疗心力衰竭的疗效

杨晓芬
甘肃省定西市安定区第二人民医院 甘肃 定西 743011

【摘 要】：目的： HF 方法： 2020 11 2021 12 CH 82 41 CH 41 CH 结果： CO cTnT LVEF NT-proBNP IGF-1 P<0.05 LVEDV Hcy LVESV hs-CRP P<0.05 97.56% 73.17% P<0.05 结论： HF

【关键词】：

## Efficacy of the Isosorbide Mononitrate for Injection in the Treatment of Heart Failure

**Xiaofen Yang**

The Second People's Hospital of Anding District Gansu Dingxi 743011

**Abstract:** Objective: To analyze the effect of isosorbide mononitrate for injection in the treatment of heart failure (HF). Methods: A total of 82 CH patients who were admitted to hospital from November 2020 to December 2021 were selected and grouped according to the order of admission. The patients in the control group were all 41 CH patients who were first admitted to the hospital (comprehensive treatment). The patients were all 41 CH patients (isosorbide mononitrate for injection) who were later admitted to the hospital, and the effects were compared. Results: The levels of CO, cTnT, LVEF, NT-proBNP, IGF-1 and quality of life in the observation group were higher than those in the control group (P<0.05); the levels of LVEDV, Hcy, LVESV, hs- The CRP levels were lower than those in the control group (P<0.05); the effective rate in the observation group was 97.56% higher than that in the control group (73.17%) (P<0.05). Conclusion: Isosorbide mononitrate for injection can effectively improve the cardiac function, slow down the development of the disease and improve the curative effect in the treatment of HF patients.

**Keywords:** Heart failure; Quality of life; Therapeutic effect; Isosorbide mononitrate for injection; Cardiac function; Markers of heart failure

HF [1]

HF [2] [3] HF

## 1 资料和方法

### 1.1

82 CH 2020 11 2021 12 41 CH 22 19 53.25 ± 0.32 41 CH 23 18 54.16 ± 0.29 P>0.05

### 1.2

H20020315 20~40mg 250ml 1 /d 10d

### 1.3

1 LVEDV LVESV LVEF CO 2 N NT-proBNP T cTnT IGF-1 3 2 1 4 Hcy C-hs-CRP 5 SF-36 4

1.4

SPSS22.0 P 0.05

2 结果

1 $\bar{x} \pm s$

| | | CO(L/min) | | LVEF(%) | | LVESV(ml) | | LVEDV ml | |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | |
| | 41 | 3.25 ± 0.42 | 4.96 ± 0.54 | 47.23 ± 3.83 | 55.66 ± 5.30 | 127.43 ± 17.66 | 108.23 ± 13.97 | 203.01 ± 32.47 | 170.76 ± 24.31 |
| | 41 | 3.27 ± 0.40 | 4.65 ± 0.50 | 46.67 ± 3.88 | 50.34 ± 5.21 | 126.53 ± 18.23 | 112.45 ± 15.12 | 199.99 ± 31.78 | 182.64 ± 25.29 |
| t | | 0.554 | 5.326 | 0.412 | 4.802 | 0.556 | 6.325 | 0.825 | 4.802 |
| P | | >0.05 | <0.05 | >0.05 | <0.05 | >0.05 | <0.05 | >0.05 | <0.05 |

2.2

1

cTnT 97.53 ± 9.45 ng/L NT-proBNP 852.13 ± 205.53 ng/L IGF-1 95.67 ± 22.12 ug/L

cTnT 95.86 ± 9.33 ng/L NT-proBNP 850.20 ± 202.52 ng/L IGF-1 98.13 ± 21.31 ug/L

t=0.882 0.336 0.114 P>0.05

2

cTnT 76.29 ± 7.86 ng/L NT-proBNP 360.40 ± 121.41 ng/L IGF-1 119.54 ± 23.96 ug/L

cTnT 86.16 ± 7.23 ng/L NT-proBNP 419.30 ± 117.60 ng/L IGF-1 114.88 ± 24.44 ug/L

t=5.823 6.339 9.325 P<0.05

2.3

32 78.05% 8 19.51%

1 2.44% 97.56% 40/41

20 48.78% 10 24.39%

11 26.83% 73.17% 30/41

$X^2$=13.502 P<0.05

2.4 Hcy hs-CRP

1

Hcy 24.26 ± 15.21 umol/l hs-CRP 4.76 ± 1.35 mg/L

Hcy 22.42 ± 14.66 umol/l hs-CRP 4.86 ± 1.24 mg/L

t=0.553 0369 P>0.05

2

Hcy 13.87 ± 8.66 umol/l hs-CRP 2.41 ± 1.13 mg/L

Hcy 16.63 ± 5.02 umol/l hs-CRP 2.96 ± 1.13 mg/L

t=6.335 5.802 P<0.05

2.1

P>0.05

P<0.05

1

2.5

1

59.25 ± 1.07 68.12 ± 1.19 64.22 ± 0.84 64.18 ± 1.33

59.24 ± 1.11 68.13 ± 1.17 64.28 ± 0.78 64.29 ± 1.35

t=0.751 0.451 0.516 0.846 P>0.05

2

92.55 ± 1.33 95.14 ± 1.28 91.47 ± 1.60 93.20 ± 0.75

73.30 ± 1.28 82.19 ± 1.16 80.27 ± 1.45 84.05 ± 0.65

t=5.952 6.221 5.445 6.285 P<0.05

3 讨论

HF

[4]

HF HF

[5] HF

HF

HF HF

HF

HF

β

Hcy

CO

Hcy Hcy CRP

LVEDV

HF HF

参考文献：

[1] .
[J]. ( ), 2019, 6(23):161,163.
[2] , , , .
[J]. ,2019, 5(23):100-101.
[3] , , .
AMI BNP hs-CRP
[J]. ( ),2021,18(3):140-143.
[4] , , .
[J]. ,2019,14(32):11-13.
[5] , , , .
[J].
, 2020,28(2):99-103.

HF NT-proBNP

IGF-1

CO

LVEF IGF-1

IGF-1

cTnT

CRP HF